Pregnancy Outcomes in Renal Transplant Recipients

Status Active, not recruiting

Clinical Trial Summary

This is a retrospective study involving all patients with a history of renal transplant that attended antenatal clinics at various Toronto hospitals and subsequently delivered between January 2000 and December 2014.

The purpose of this study is to describe the incidence of adverse pregnancy-and transplant-related outcomes, and report placental ultrasound and placental pathology findings in renal transplant recipients with contemporary standards of care in Toronto.

This study also seeks to determine whether factors such as maternal age, transplant-to-pregnancy interval, hypertension, diabetes mellitus, treatment regimens, and the primary cause for renal failure are associated with higher risk of adverse pregnancy outcomes in renal transplant recipients.

Clinical Trial Description

Adverse pregnancy outcomes in women with renal transplants have been attributed to a number of factors. A recent systematic review suggested an association between maternal age and adverse pregnancy outcomes such as miscarriage and stillbirth. There are also some data to suggest that maternal hypertension, diabetes mellitus, elevated serum creatinine and proteinuria and some medications such as cyclosporine are associated with adverse pregnancy outcomes such as preeclampsia, intrauterine growth restriction and preterm delivery.There is no consensus on whether the transplant-to-pregnancy interval is associated with adverse pregnancy outcomes. As well, it is not clear if the findings of other studies will also hold true in a Toronto population.

This study seeks to answer the following questions:

1. What is the incidence of adverse transplant- and pregnancy-related adverse outcomes in renal transplant recipients that have had pregnancies between 2000 and 2014 in Toronto and how does this compare with earlier data from Toronto and with recently published data?

2. Are factors such as maternal age, transplant-to-pregnancy interval, hypertension, diabetes mellitus, specific treatment regimens and the primary cause for renal failure associated with an increased risk of adverse pregnancy- and transplant-related adverse outcomes in these women? ;

Study Design

Related Conditions & MeSH terms

Renal Transplant

Clinical Trial Details

NCT number	NCT03073434
Study type	Observational
Source	St. Michael's Hospital, Toronto
Contact
Status	Active, not recruiting
Phase
Start date	March 1, 2016
Completion date	March 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01220050` - Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism	Phase 2
Completed	`NCT00820469` - Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab	Phase 4
Completed	`NCT00239005` - Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation	Phase 4
Completed	`NCT00270153` - The Use of ACE Inhibitors in the Early Renal Post-transplant Period	Phase 1
Completed	`NCT02711826` - Treg Therapy in Subclinical Inflammation in Kidney Transplantation	Phase 1/Phase 2
Completed	`NCT03837522` - Trial to Define the Benefits and Harms of Deceased Donor Kidney Procurement Biopsies	N/A
Not yet recruiting	`NCT06025240` - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Completed	`NCT01256294` - Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients	Phase 4
Suspended	`NCT01059292` - TIPE2 Associated With Kidney Transplant	N/A
Completed	`NCT00547040` - Arterial Stiffness and Calcifications in Incident Renal Transplant Recipients
Suspended	`NCT03043339` - Characterization Of the Intestinal Microbiome Evolution After Kidney Transplant Donation or Receipt
Completed	`NCT02581644` - Assessment of Effectiveness of Belatacept Patient Alert Card in Patients Following Renal Transplantation in a Sample of EU Countries	N/A
Completed	`NCT01728012` - Long-term Cardiovascular Risk Following Successful Renal Transplantation	N/A
Terminated	`NCT01011114` - Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant	N/A
Completed	`NCT02117596` - Calcineurin Inhibitor Based Immunosuppression Withdrawal	N/A
Completed	`NCT00555373` - Pediatric Kidney Transplant Study of Sirolimus, Mycophenolate Mofetil, and Corticosteroids vs Calcineurin Inhibitor Based Immunosuppression	N/A
Recruiting	`NCT05156086` - Safety and Effectiveness of COVID-19 Vaccine in Kidney Transplant Recipients
Completed	`NCT01334333` - Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients	Phase 4
Recruiting	`NCT03107858` - The Effect of Norepinephrine Versus Dopamine in Renal Transplant Recipients on Postoperative Graft Function	Phase 2/Phase 3
Completed	`NCT00352547` - Influence of Genes on Sirolimus Metabolism in Patients With Kidney Transplantation	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.